The Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy drugs in development market research report provides comprehensive information on the therapeutics under development for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy and features dormant and discontinued products.
GlobalData tracks 70 drugs in development for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy by 69 companies/universities/institutes. The top development phase for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy is phase ii with 36 drugs in that stage. The Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy pipeline has 62 drugs in development by companies and eight by universities/ institutes. Some of the companies in the Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy pipeline products market are: Bristol-Myers Squibb, CSPC Pharmaceutical Group and Nanchang University Affiliated Hospital One.
The key targets in the Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy pipeline products market include Tumor Necrosis Factor Receptor Superfamily Member 8, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, and Histone Deacetylase.
The key mechanisms of action in the Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy pipeline product include Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor with six drugs in Pre-Registration. The Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy pipeline products include eight routes of administration with the top ROA being Intravenous and seven key molecule types in the Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy pipeline products market including Small Molecule, and Gene-Modified Cell Therapy.
Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy overview
Angioimmunoblastic T-cell lymphoma (AITL), previously known as immunoblastic lymphadenopathy, is a rare and aggressive form of peripheral T-cell lymphoma that originates from mature T cells in the immune system. AITL typically affects individuals in late adulthood and often presents with generalized symptoms including enlarged lymph nodes, fever, night sweats, weight loss, skin rashes, and an increased risk of infections. It is characterized by a specific pattern of lymph node changes, often accompanied by the presence of abnormal cells called Reed-Sternberg-like cells. Diagnosis of AITL involves a series of tests, including biopsies of enlarged lymph nodes, blood tests, imaging studies (such as CT scans), and sometimes genetic or molecular analyses to confirm the presence of characteristic markers or mutations associated with the disease.
For a complete picture of Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
